Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
This study consists of a 12-week base study (MK2578-003-AM03) and an optional 40-week extension study (MK2578-003-EXT12). Participants who complete 12 weeks of treatment in the base study will enter the extension on the most recent dose administered in the base study or a newly adjusted dose, if adjustment is required to bring Hg levels within range. Participants' doses of MK2578 will be adjusted upward or downward during the extension study to maintain Hb in the range of 10-12 g/dL.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Base Study:
Patient is male or is a female who either cannot have children or who agrees to use appropriate contraceptive measures
Patient has been on hemodialysis for at least 6 months when informed consent is signed
Patient has received intravenous epoetin alfa or epoetin beta for a least 6 months when the informed consent is signed
Extension Study:
Patient completed the base study through Week 12
Patient tolerated MK2578 and demonstrated compliance with study procedures
You may not be if
Patient has a life expectancy of less than 6 months
Patient is scheduled for a kidney transplant within the next 6 months
Patient has had a blood transfusion within 12 weeks of screening
Patient has had major surgery within 12 weeks of screening or plans to have surgery
Patient has Human Immunodeficiency Virus (HIV)
Patient has history of blood dyscrasia, hematologic disorders or any other disease known to cause anemia
Patient has severe congestive heart failure (CHF)
Patient has a history of malignant cancer, except certain skin or cervical cancers
Patient has a history of grand mal seizures within the last 6 months
Clareo Health | A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12)
